Diagonal Therapeutics

Curated by Signal

Developer of antibody therapeutics for the treatment of rare diseases

Overview

Developer of antibody therapeutics for the treatment of rare diseases. The company's DIAGONAL platform combines proprietary computational and experimental techniques to develop agonist antibody therapies for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.

Key facts

Founded: 2022
Headquarters: Cambridge, United States
Stage: Sign up to view
Industry: Life Sciences Technology

Business model

3 products and services: Sign up to view

Contact

Email: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

OncoScore
Algorithms and image-based biomarkers for cancer detection
Life Sciences TechnologyRockville, United States
IMS
Provider of a wearable smart sensor for glucose monitoring
Life Sciences TechnologyOrange, United States
Personalis
Provider of genomic sequencing and diagnosis software for the healthcare industry
Life Sciences TechnologyMenlo Park, United States

About Diagonal Therapeutics

What does Diagonal Therapeutics do?

Developer of antibody therapeutics for the treatment of rare diseases.

Where is Diagonal Therapeutics headquartered?

Diagonal Therapeutics is headquartered in Cambridge, United States.

When was Diagonal Therapeutics founded?

Diagonal Therapeutics was founded in 2022.

Which sector is Diagonal Therapeutics in?

Diagonal Therapeutics operates in Life Sciences Technology.

Who are Diagonal Therapeutics's competitors?

Companies similar to Diagonal Therapeutics include OncoScore, IMS, and Personalis.